13:@0.950592:0.038669:0.976697:0.038669:0.976697:0.018636:0.950592:0.018636:0.000000:0.000000
TreaTmenT approaches:@0.614842:0.039914:0.902661:0.039914:0.902661:0.020479:0.614842:0.020479:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
MIMS ConCISe GuIde to CardIovaSCular, MetabolIC and endoCrIne dISeaSeS :@0.216640:0.974259:0.820834:0.974259:0.820834:0.960936:0.216640:0.960936:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
 :@0.820834:0.974259:0.824580:0.974259:0.824580:0.960936:0.820834:0.960936:0.000000
VOLUME 1:@0.824751:0.974259:0.906065:0.974259:0.906065:0.959690:0.824751:0.959690:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
cardiac diseases:@0.977306:0.274107:0.977306:0.127972:0.949036:0.127972:0.949036:0.274107:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
Prof B Rayner:@0.096970:0.206921:0.225359:0.206921:0.225359:0.188709:0.096970:0.188709:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
mBchB, Fcp, mmed, phd:@0.096970:0.221458:0.292145:0.221458:0.292145:0.205556:0.096970:0.205556:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
Emeritus Professor, Division of Nephrology and :@0.096970:0.236367:0.437137:0.236367:0.437137:0.221643:0.096970:0.221643:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
Hypertension, Department of Medicine, University  :@0.096970:0.251276:0.464384:0.251276:0.464384:0.236552:0.096970:0.236552:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
of Cape Town, Cape Town:@0.096970:0.266186:0.284775:0.266186:0.284775:0.251461:0.096970:0.251461:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
Cardiovascular disease is the leading cause of :@0.096970:0.295991:0.479970:0.295991:0.479970:0.281002:0.096970:0.281002:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
death worldwide.  In 2013 in sub-Saharan africa :@0.096970:0.310900:0.479980:0.310881:0.479980:0.295892:0.096970:0.295911:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
1:@0.233322:0.305097:0.238796:0.305097:0.238796:0.296358:0.233322:0.296358:0.000000
alone, there were approximately one million :@0.096980:0.325790:0.479980:0.325790:0.479980:0.310802:0.096980:0.310802:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
associated deaths.  Hypertension  is the  most :@0.096980:0.340700:0.479970:0.340689:0.479970:0.325700:0.096980:0.325711:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
2:@0.243933:0.334904:0.249407:0.334904:0.249407:0.326166:0.243933:0.326166:0.000000
important modifiable risk factor for preventing :@0.096969:0.355598:0.479970:0.355598:0.479970:0.340610:0.096969:0.340610:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
cardiovascular disease (Cv) disease in africa, but :@0.096969:0.370507:0.479970:0.370507:0.479970:0.355519:0.096969:0.355519:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
there is a considerable unmet need.  according :@0.096969:0.385417:0.479970:0.385417:0.479970:0.370428:0.096969:0.370428:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
to the late Professor bongani Mayosi, controlling :@0.096969:0.400326:0.479989:0.400326:0.479989:0.385337:0.096969:0.385337:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
hypertension is the number one best buy for :@0.096969:0.415235:0.479970:0.415235:0.479970:0.400247:0.096969:0.400247:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
preventing heart disease in africa.:@0.096969:0.430145:0.356087:0.430145:0.356087:0.415156:0.096969:0.415156:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
3:@0.356083:0.424328:0.361558:0.424328:0.361558:0.415589:0.356083:0.415589:0.000000
there is an estimated 35.1% prevalence :@0.115151:0.445016:0.479949:0.445016:0.479949:0.430028:0.115151:0.430028:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
of hypertension in the South  african adult :@0.096967:0.459925:0.479968:0.459925:0.479968:0.444937:0.096967:0.444937:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
population, but control rates remain suboptimal. :@0.096967:0.474835:0.479949:0.474835:0.479949:0.459846:0.096967:0.459846:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
approximately 90% of people with hypertension :@0.096967:0.489744:0.480006:0.489744:0.480006:0.474755:0.096967:0.474755:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
are uncontrolled due to lack of screening, failure :@0.096967:0.504653:0.480006:0.504653:0.480006:0.489665:0.096967:0.489665:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
to  treat  those  diagnosed  or  failure  to  achieve :@0.096967:0.519563:0.479910:0.519563:0.479910:0.504574:0.096967:0.504574:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
target blood pressure (bP). Consequently, these :@0.096967:0.534472:0.479968:0.534472:0.479968:0.519483:0.096967:0.519483:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
people are at risk for adverse Cv events.  :@0.096967:0.549381:0.408604:0.549343:0.408604:0.534355:0.096967:0.534392:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
4:@0.398916:0.543559:0.404390:0.543559:0.404390:0.534821:0.398916:0.534821:0.000000
this short review will update practitioners on :@0.115157:0.564253:0.479936:0.564253:0.479936:0.549264:0.115157:0.549264:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
the  most recent developments in  diagnosis and :@0.096973:0.579162:0.479993:0.579162:0.479993:0.564173:0.096973:0.564173:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
management of hypertension in the last few years.:@0.096973:0.594071:0.475471:0.594071:0.475471:0.579083:0.096973:0.579083:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
Definition of hypertension :@0.097205:0.625869:0.429568:0.625869:0.429568:0.606110:0.097205:0.606110:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
anD target blooD pressure:@0.097205:0.644447:0.424605:0.644447:0.424605:0.624688:0.097205:0.624688:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
In 2018, the american Heart association/american :@0.096970:0.659204:0.479970:0.659204:0.479970:0.644216:0.096970:0.644216:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
College of Cardiology Hypertension guideline :@0.096970:0.674696:0.479951:0.674696:0.479951:0.659707:0.096970:0.659707:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
hypertension: new developments  :@0.096970:0.112731:0.738640:0.112731:0.738640:0.076807:0.096970:0.076807:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
in diagnosis and treatment:@0.096970:0.145069:0.592953:0.145069:0.592953:0.109145:0.096970:0.109145:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
published  a  comprehensive  overview  for  the :@0.524242:0.207951:0.907204:0.207951:0.907204:0.192963:0.524242:0.192963:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
prevention, detection, evaluation, and management :@0.524242:0.222384:0.907224:0.222384:0.907224:0.207396:0.524242:0.207396:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
of high bP in adults.  this is an excellent guideline, :@0.524242:0.236818:0.907253:0.236821:0.907253:0.221833:0.524242:0.221829:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
5:@0.674653:0.231037:0.680128:0.231037:0.680128:0.222298:0.674653:0.222298:0.000000
but it controversially redefined hypertension and, :@0.524252:0.251254:0.907272:0.251254:0.907272:0.236266:0.524252:0.236266:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
arising from this, a change in target bP.  the Guideline :@0.524252:0.265687:0.907253:0.265687:0.907253:0.250699:0.524252:0.250699:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
defined hypertension as a bP ≥130 systolic and/or :@0.524252:0.280120:0.907291:0.280120:0.907291:0.265132:0.524252:0.265132:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
diastolic ≥80 mmHg on at least two occasions, and :@0.524252:0.294553:0.907291:0.294553:0.907291:0.279565:0.524252:0.279565:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
the target bP <130/80 mmHg for most patients. no :@0.524252:0.308986:0.907195:0.308986:0.907195:0.293998:0.524252:0.293998:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
lower threshold was defined. :@0.524252:0.323419:0.739594:0.323419:0.739594:0.308431:0.524252:0.308431:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
In 2019, the  european Society of Cardiology/:@0.542436:0.337852:0.903019:0.337852:0.903019:0.322864:0.542436:0.322864:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
european Society of Hypertension also published :@0.524252:0.352285:0.907272:0.352285:0.907272:0.337297:0.524252:0.337297:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
a comprehensive guideline, but the definition :@0.524252:0.366719:0.907272:0.366719:0.907272:0.351730:0.524252:0.351730:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
 :@0.903039:0.366719:0.907253:0.366719:0.907253:0.351730:0.903039:0.351730:0.000000
of  hypertension  was  left  unchanged  at  :@0.524252:0.381152:0.907253:0.381152:0.907253:0.366163:0.524252:0.366163:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
≥140/90 mmHg.  However, target bP was defined :@0.524252:0.395585:0.907282:0.395606:0.907282:0.380617:0.524252:0.380596:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
6:@0.650790:0.389821:0.656265:0.389821:0.656265:0.381083:0.650790:0.381083:0.000000
in terms of age and underlying comorbidity (see :@0.524243:0.410039:0.907282:0.410039:0.907282:0.395050:0.524243:0.395050:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
table  1).  In  general,  targets  were  reduced  to :@0.524243:0.424472:0.907186:0.424472:0.907186:0.409483:0.524243:0.409483:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
<130/80 mmHg for individuals <65 years if tolerated, :@0.524243:0.438905:0.907282:0.438905:0.907282:0.423916:0.524243:0.423916:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
but not lower than 120 mmHg systolic and between :@0.524243:0.453338:0.907263:0.453338:0.907263:0.438349:0.524243:0.438349:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
70-80 mmHg diastolic. In older persons >65 years, :@0.524243:0.467771:0.907243:0.467771:0.907243:0.452782:0.524243:0.452782:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
systolic target was between 130-140 mmHg systolic :@0.524243:0.482204:0.907263:0.482204:0.907263:0.467215:0.524243:0.467215:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
with the same diastolic goal.:@0.524243:0.496637:0.730906:0.496637:0.730906:0.481648:0.524243:0.481648:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
the South  african Hypertension Society :@0.542427:0.511070:0.907263:0.511070:0.907263:0.496081:0.542427:0.496081:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
recommends a universal target <140/90 mmHg :@0.524243:0.525503:0.907205:0.525503:0.907205:0.510514:0.524243:0.510514:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
and if tolerated <130/80 mmHg in individuals at :@0.524243:0.539936:0.907224:0.539936:0.907224:0.524947:0.524243:0.524947:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
high risk.   this decision was largely pragmatic, :@0.524243:0.554369:0.907234:0.554390:0.907234:0.539401:0.524243:0.539380:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
7:@0.597172:0.548606:0.602646:0.548606:0.602646:0.539867:0.597172:0.539867:0.000000
based on the high levels of uncontrolled bP in the :@0.524233:0.568823:0.907177:0.568823:0.907177:0.553834:0.524233:0.553834:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
population, simplicity of the recommendation :@0.524233:0.583256:0.907215:0.583256:0.907215:0.568267:0.524233:0.568267:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
and the resources needed to screen and treat the :@0.524233:0.597689:0.907234:0.597689:0.907234:0.582700:0.524233:0.582700:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
increased number of patients. :@0.524233:0.612122:0.756951:0.612122:0.756951:0.597133:0.524233:0.597133:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
Diagnosis of hypertension:@0.524477:0.644503:0.847268:0.644503:0.847268:0.624745:0.524477:0.624745:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
both the eSC/eSH and the aCC/aHa hypertension :@0.524242:0.659232:0.907243:0.659232:0.907243:0.644244:0.524242:0.644244:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
guidelines emphasise the need for appropriate :@0.524242:0.674697:0.907281:0.674697:0.907281:0.659709:0.524242:0.659709:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
Table 1. Esc/EsHblood pressure targets 2018:@0.096964:0.717401:0.475770:0.717401:0.475770:0.701010:0.096964:0.701010:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
Age:@0.105522:0.752350:0.135540:0.752350:0.135540:0.737780:0.105522:0.737780:0.000000:0.000000:0.000000
Office sBP target ranges (mmHg):@0.166276:0.752350:0.414734:0.752350:0.414734:0.737780:0.166276:0.737780:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
DBP:@0.843849:0.752350:0.876022:0.752350:0.876022:0.737780:0.843849:0.737780:0.000000:0.000000:0.000000
Hypertension:@0.166276:0.779431:0.270425:0.779431:0.270425:0.764861:0.166276:0.764861:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
+DM:@0.302034:0.779431:0.338603:0.779431:0.338603:0.764861:0.302034:0.764861:0.000000:0.000000:0.000000
+cKD:@0.443846:0.779431:0.486624:0.779431:0.486624:0.764861:0.443846:0.764861:0.000000:0.000000:0.000000:0.000000
+cAD:@0.575960:0.779431:0.619627:0.779431:0.619627:0.764861:0.575960:0.764861:0.000000:0.000000:0.000000:0.000000
+cVA/TIA:@0.708074:0.779431:0.780904:0.779431:0.780904:0.764861:0.708074:0.764861:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
18-65:@0.105505:0.802221:0.143989:0.802221:0.143989:0.788897:0.105505:0.788897:0.000000:0.000000:0.000000:0.000000:0.000000
<:@0.166259:0.802714:0.173854:0.802714:0.173854:0.788568:0.166259:0.788568:0.000000
130 or lower*, :@0.173854:0.802714:0.272358:0.802714:0.272358:0.789391:0.173854:0.789391:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
not  120:@0.166259:0.816238:0.226193:0.816238:0.226193:0.802914:0.166259:0.802914:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
<:@0.193558:0.816238:0.201152:0.816238:0.201152:0.802091:0.193558:0.802091:0.000000
<:@0.302017:0.802714:0.309611:0.802714:0.309611:0.788568:0.302017:0.788568:0.000000
130 or lower* :@0.309611:0.802714:0.405139:0.802714:0.405139:0.789391:0.309611:0.789391:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
not 120:@0.302017:0.816238:0.362002:0.816238:0.362002:0.802914:0.302017:0.802914:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
 <:@0.325569:0.816238:0.336961:0.816238:0.336961:0.802091:0.325569:0.802091:0.000000:0.000000
<:@0.443829:0.802714:0.451423:0.802714:0.451423:0.788568:0.443829:0.788568:0.000000
140 or lower* :@0.451423:0.802714:0.546951:0.802714:0.546951:0.789391:0.451423:0.789391:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
not 130:@0.443829:0.816238:0.503814:0.816238:0.503814:0.802914:0.443829:0.802914:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
 <:@0.467382:0.816238:0.478773:0.816238:0.478773:0.802091:0.467382:0.802091:0.000000:0.000000
<:@0.575943:0.802714:0.583537:0.802714:0.583537:0.788568:0.575943:0.788568:0.000000
130 or lower* :@0.583537:0.802714:0.679065:0.802714:0.679065:0.789391:0.583537:0.789391:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
not 120:@0.575943:0.816238:0.635928:0.816238:0.635928:0.802914:0.575943:0.802914:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
 <:@0.599496:0.816238:0.610887:0.816238:0.610887:0.802091:0.599496:0.802091:0.000000:0.000000
<:@0.708057:0.802714:0.715651:0.802714:0.715651:0.788568:0.708057:0.788568:0.000000
130 or lower* :@0.715651:0.802714:0.811179:0.802714:0.811179:0.789391:0.715651:0.789391:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
not 120:@0.708057:0.816238:0.768042:0.816238:0.768042:0.802914:0.708057:0.802914:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
 <:@0.731610:0.816238:0.743001:0.816238:0.743001:0.802091:0.731610:0.802091:0.000000:0.000000
70-79:@0.843814:0.802221:0.882299:0.802221:0.882299:0.788897:0.843814:0.788897:0.000000:0.000000:0.000000:0.000000:0.000000
65-79:@0.105488:0.840074:0.143972:0.840074:0.143972:0.826750:0.105488:0.826750:0.000000:0.000000:0.000000:0.000000:0.000000
130-139*:@0.166242:0.840074:0.228109:0.840074:0.228109:0.826750:0.166242:0.826750:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
130-139*:@0.301999:0.840074:0.363866:0.840074:0.363866:0.826750:0.301999:0.826750:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
130-139*:@0.443812:0.840074:0.505678:0.840074:0.505678:0.826750:0.443812:0.826750:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
130-139*:@0.575926:0.840074:0.637792:0.840074:0.637792:0.826750:0.575926:0.826750:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
130-139*:@0.708040:0.840074:0.769906:0.840074:0.769906:0.826750:0.708040:0.826750:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
70-79:@0.843797:0.840074:0.882282:0.840074:0.882282:0.826750:0.843797:0.826750:0.000000:0.000000:0.000000:0.000000:0.000000
>:@0.105470:0.867402:0.113065:0.867402:0.113065:0.853256:0.105470:0.853256:0.000000
80:@0.113065:0.867402:0.129759:0.867402:0.129759:0.854079:0.113065:0.854079:0.000000:0.000000
130-139*:@0.166225:0.867155:0.228092:0.867155:0.228092:0.853832:0.166225:0.853832:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
130-139*:@0.301982:0.867155:0.363849:0.867155:0.363849:0.853832:0.301982:0.853832:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
130-139*:@0.443795:0.867155:0.505661:0.867155:0.505661:0.853832:0.443795:0.853832:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
130-139*:@0.575909:0.867155:0.637775:0.867155:0.637775:0.853832:0.575909:0.853832:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
130-139*:@0.708023:0.867155:0.769889:0.867155:0.769889:0.853832:0.708023:0.853832:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
70-79:@0.843780:0.867155:0.882265:0.867155:0.882265:0.853832:0.843780:0.853832:0.000000:0.000000:0.000000:0.000000:0.000000
dbP:@0.105453:0.893202:0.133744:0.893202:0.133744:0.879879:0.105453:0.879879:0.000000:0.000000:0.000000
70-79:@0.166208:0.893202:0.204693:0.893202:0.204693:0.879879:0.166208:0.879879:0.000000:0.000000:0.000000:0.000000:0.000000
70-79:@0.301965:0.893202:0.340450:0.893202:0.340450:0.879879:0.301965:0.879879:0.000000:0.000000:0.000000:0.000000:0.000000
70-79:@0.443778:0.893202:0.482262:0.893202:0.482262:0.879879:0.443778:0.879879:0.000000:0.000000:0.000000:0.000000:0.000000
70-79:@0.575892:0.893202:0.614376:0.893202:0.614376:0.879879:0.575892:0.879879:0.000000:0.000000:0.000000:0.000000:0.000000
70-79:@0.708006:0.893202:0.746491:0.893202:0.746491:0.879879:0.708006:0.879879:0.000000:0.000000:0.000000:0.000000:0.000000
dM – diabetes mellitus, CKd – chronic kidney disease, Cad – coronary artery disease, Cva – cerebrovascular accident, tIa – transient :@0.096970:0.924039:0.886517:0.924039:0.886517:0.912382:0.096970:0.912382:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
ischaemic attack, SbP – systolic bP, dbP – diastolic bP, * if tolerated:@0.096970:0.935872:0.491033:0.935872:0.491033:0.924214:0.096970:0.924214:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000